Linkins Lori-Ann
Department of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, Canada.
Vasc Health Risk Manag. 2008;4(2):279-87. doi: 10.2147/vhrm.s2132.
Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.
癌症是静脉血栓栓塞症（VTE）发生的主要风险因素。对于癌症患者，使用维生素K拮抗剂进行传统抗凝治疗存在更多问题，因为复发性VTE风险增加，且抗凝相关出血风险也增加。近年来，在治疗患有VTE的癌症患者时，已转向使用延长疗程的达肝素。达肝素是一种低分子肝素，已证明在患有VTE的癌症患者中比传统抗凝治疗更有效且同样安全。本文将（a）综述癌症与VTE之间的关系，以及（b）概述达肝素在癌症患者VTE管理中的作用。
